Human data. Real confidence.
We are the gold-standard partner to drug developers. Combining our proprietary bioreactor technology and ex-vivo precision-cut tissue slices (PCTS), to bridge the translational gap and better predict clinical outcomes.
Does your data reflect human reality?
Defensible data designed for confident decisions when the cost of being wrong is greatest.
Target identification and validation
Interrogate novel therapeutic targets in intact, viable human tissue to build the real biological evidence needed to support confident early decisions.
Lead screening and optimization
Test and rank novel interventions early to generate the decision-grade data needed to prioritize stronger candidates and enhance preclinical confidence.
Pharmacology
Gain direct evidence of target engagement in intact human tissue to strengthen the translational case behind your program and support IND-enabling submissions.
Drug safety
Assess tissue viability and emerging safety signals in intact human tissue to identify weak assets early and avoid unnecessary progression into formal GLP studies.
The ultimate preclinical assurance
Combining the benefits of ex-vivo PCTS and our proprietary bioreactor technology, our platform delivers the definitive, human-relevant evidence needed to advance your drug discovery and development with confidence.
Tissue bioreactor technology
Proprietary bioreactor systems designed to preserve native tissue structure and function, enabling controlled, extended study in living human tissue.
Tissue types and indications
Ethical procurement of viable human liver, lung and kidney tissue through established clinical partnerships for use in our PCTS platforms.
Confidence built on real human biology
FibroFind is a preclinical CRO supporting biopharmaceutical organisations worldwide. Founded by world-leading experts, we uphold a defining ambition to de-risk drug discovery and development through the gold standard in human-relevant evidence, translating the irreplaceable complexity of human disease into evidence that moves programmes forward with confidence.
Led by recognized experts
Our executive leadership brings internationally recognized expertise in disease biology, translational science and human tissue research. FibroFind was founded by Professors Jelena Mann, Derek Mann, Fiona Oakley and Dr. Lee Borthwick, whose work helped establish the scientific foundations of the business.
Today, our wider leadership team builds on that legacy, combining deep academic, clinical and commercial expertise to guide global biopharma sponsors and translate complex scientific insight into decision-grade pipeline strategy.
The evidence your program demands
Speak to our team about your programme.